《大行报告》野村上调康宁杰瑞制药-B(09966.HK)目标价至28.8元 评级「买入」
野村发表研报指,康宁杰瑞制药(09966.HK)於美国临床肿瘤学会年会发布产品KN046及KN026的研究结果。
数据显示,KN046作为一线疗法,用於治疗鳞状非小细胞肺癌及胰脏癌的成功率估算已由50%提升至75%及80%,而KN026作为二线疗法治疗胃癌或胃食管结合部癌及乳癌的成功率亦由25%提升至50%。
野村表示,期望KN046的第三期临床试验可进一步改善疗效及得出更安全数据,包括对治疗相关不良事件(TRAE)及作出更具体描述,又指KN026的临床数据及安全性均向好。根据研究结果,野村对康宁杰瑞维持「买入」评级,目标价由25.1元上调15%至28.8元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.